Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 10 sources cited · As of May 2026, confirm directly with your plan
Key Takeaways
- Ambetter is Centene's Affordable Care Act marketplace brand, operating in approximately 30 states
- Each state Ambetter plan operates separately with its own formulary and benefit design
- Coverage of Zepbound varies dramatically by state and metal tier (Bronze, Silver, Gold)
- The ACA does not mandate Zepbound coverage; essential health benefit benchmarks determine minimum requirements
- The December 2024 OSA indication provides an alternative pathway in many state plans
Direct answer
Ambetter's coverage of Zepbound varies dramatically across its 30 state markets. As a Centene-owned ACA marketplace brand, each state Ambetter affiliate operates separately with state-specific formulary decisions. Some state Ambetter plans cover Zepbound for obesity with prior authorization; others exclude anti-obesity medications. The December 2024 OSA indication has expanded coverage paths across multiple state plans. Check your specific state Ambetter formulary and metal tier benefit structure.
See transparent compounded pricing
Review compounded GLP-1 pricing and what provider-reviewed care includes, with no surprises at checkout.
Try the Cost Calculator →Table of contents
- Ambetter's marketplace footprint
- How ACA marketplace plans differ from commercial group plans
- Essential health benefits and Zepbound coverage
- State-by-state variation in Ambetter coverage
- Metal tier effects on out-of-pocket cost
- The December 2024 OSA pathway
- Prior authorization mechanics
- Cost scenarios across metal tiers
- The compounded semaglutide question for marketplace members
- Appealing an Ambetter denial
- Decision framework
- FAQ
- Sources
Ambetter's marketplace footprint
Ambetter operates as the Affordable Care Act marketplace brand for Centene Corporation. Ambetter plans are sold through HealthCare.gov (the federal marketplace) and state-based exchanges in approximately 30 states. Centene markets these plans under variations of the Ambetter name including:
- Ambetter from Sunshine Health (Florida)
- Ambetter of Texas
- Ambetter Health (multiple states)
- State-specific brand names that incorporate Ambetter or Centene affiliations
Each state affiliate operates as a separately licensed insurer with state insurance department oversight. State-specific essential health benefit benchmarks, formulary requirements, and market dynamics shape coverage.
How ACA marketplace plans differ from commercial group plans
Marketplace plans have distinct structural features:
- Sold to individuals and families, not employers
- Subject to ACA essential health benefit requirements
- Premiums and cost-sharing subsidies available based on income
- Annual enrollment periods (open enrollment plus qualifying life events)
- Metal tier structure (Bronze, Silver, Gold, Platinum) determining cost-sharing
- State-specific formulary and benefit decisions
- Income-based cost-sharing reductions available for Silver-tier enrollees up to 250% FPL
These features shape Zepbound coverage. Bronze plans typically have higher specialty drug copays; Gold plans have lower. Income-based subsidies can substantially reduce out-of-pocket costs.
Essential health benefits and Zepbound coverage
The ACA requires marketplace plans to cover essential health benefits in 10 categories, including prescription drugs. The specific drugs covered are determined by state benchmark plans rather than federal mandate.
State benchmark plans are typically modeled on a large employer plan or state employee plan in each state. The benchmark determines:
- Minimum number of drugs covered in each therapeutic class
- Whether anti-obesity medications are included in the formulary
- Step therapy and prior authorization frameworks
States vary in whether their benchmark plans include anti-obesity drug coverage. This produces the wide variation in Ambetter Zepbound coverage across state markets.
State-by-state variation in Ambetter coverage
Ambetter Zepbound coverage as of May 2026 (illustrative; verify current state formularies):
| State Ambetter affiliate | Typical Zepbound coverage |
|---|---|
| Florida | Coverage available with PA; OSA pathway expanded |
| Texas | Variable; often restricted to OSA indication |
| Georgia | Limited coverage; OSA pathway primary |
| North Carolina | Coverage with PA in some plans |
| Illinois | Coverage available with PA |
| California (Health Net) | Coverage with PA; California-specific mandates apply |
| Other states | Highly variable; check specific state plan |
The pattern is irregular. Members should not assume Ambetter Zepbound coverage is similar across states even when prescribed by the same physician under the same clinical circumstances.
Metal tier effects on out-of-pocket cost
ACA metal tiers determine cost-sharing structure:
| Metal tier | Plan pays | Member pays | Typical specialty drug copay |
|---|---|---|---|
| Platinum | ~90% | ~10% | $50 to $100 |
| Gold | ~80% | ~20% | $100 to $200 |
| Silver | ~70% | ~30% | $150 to $300 |
| Bronze | ~60% | ~40% | $200 to $400 or coinsurance |
Members enrolled in Silver plans with incomes between 100% and 250% of federal poverty level qualify for cost-sharing reductions (CSRs) that effectively raise the Silver actuarial value toward Gold or Platinum levels. The CSR makes a meaningful difference in specialty drug out-of-pocket exposure.
The December 2024 OSA pathway
The FDA's December 2024 approval of tirzepatide for moderate-to-severe OSA in adults with obesity created a new coverage pathway for Ambetter members. State Ambetter plans that excluded anti-obesity drugs have begun adding Zepbound under the OSA indication because sleep medicine is typically a covered category even when obesity drugs are excluded.
The pathway has expanded steadily through 2025 and into 2026 across Ambetter state plans. Coverage requirements typically include:
- Polysomnography confirming AHI 15+
- BMI 30 or higher
- CPAP intolerance, insufficiency, or contraindication
- Sleep medicine physician co-signature
Prior authorization mechanics
Ambetter PA processes vary by state affiliate but generally include:
- Prescriber submits PA via Centene/Ambetter provider portal
- Required documentation: BMI, comorbidities, weight-management program, or for OSA, sleep study results
- Clinical review against state-specific formulary criteria
- Decision typically within 24 to 72 hours
- Initial approval typically 6 months
Denial reasons reflect either missing documentation, failed step therapy, or categorical exclusions specific to the state Ambetter plan.
Cost scenarios across metal tiers
| Scenario | Approximate monthly cost |
|---|---|
| Gold plan covered, tier 3 | $100 to $200 |
| Silver with CSR, covered | $50 to $150 |
| Bronze plan covered | $200 to $400 or coinsurance percentage |
| With Lilly Savings Card | $25 to $50 (eligibility-limited) |
| Uncovered cash retail | Approximately $1,000 |
| LillyDirect 2.5 mg vial | Approximately $349 |
| LillyDirect 5 mg vial | Approximately $499 |
The annual out-of-pocket maximum applies. For 2026, the federal maximum is approximately $9,200 for individual plans and $18,400 for family plans (subject to ACA annual adjustment). Members hitting the out-of-pocket maximum have $0 additional cost for the year.
The compounded semaglutide question for marketplace members
Marketplace members denied Zepbound coverage sometimes turn to compounded semaglutide or compounded tirzepatide from telehealth platforms. The FDA's October 2024 declaration that semaglutide was no longer in shortage triggered enforcement against many compounders.
Distinctions for Ambetter members considering compounded alternatives:
- Compounded tirzepatide is not Zepbound; different product, different regulatory status
- Compounded preparations are not FDA-approved
- Ambetter does not cover compounded medications
- Telehealth-sourced compounded GLP-1s involve direct patient payment, not insurance reimbursement
Appealing an Ambetter denial
Ambetter appeal pathway:
- Internal first-level appeal to Centene/Ambetter clinical review
- Internal second-level appeal if available
- External review through state Independent Review Organization
The ACA requires marketplace plans to provide both internal appeals and external review. Each state has specific external review procedures and deadlines.
For OSA denials: include complete polysomnography reports, CPAP trial documentation, and sleep medicine physician supporting letter. For obesity denials: emphasize BMI history, comorbidities, and prior interventions.
Decision framework
If your state Ambetter plan covers Zepbound: Submit standard PA with appropriate documentation. Check your metal tier copay structure.
If your state Ambetter plan excludes anti-obesity drugs: Pursue the OSA indication if applicable. The pathway often produces coverage even when obesity-only requests fail.
If you have moderate-to-severe OSA: Work with sleep medicine for OSA-indication PA. Documentation is the key to approval.
If you have income at or below 250% FPL on a Silver plan: Verify cost-sharing reduction status, which substantially reduces specialty drug copays.
If denied: File internal appeals. Pursue external review through state IRO. Each state's process has specific deadlines.
What to verify before using this answer
The useful next step for Ambetter and Zepbound: The Marketplace Plan Reality is to verify the details that can change the decision: current labeling, insurance rules, pharmacy instructions, dose timing, contraindications, and whether the evidence applies to your diagnosis rather than only to weight loss headlines.
For this coverage and access page, the most relevant search terms are does, ambetter, cover, zepbound. Those terms point to a practical decision, so the answer should be checked against a current prescription label, payer policy, trial result, or clinician recommendation before you act.
FormBlends keeps this page focused on patient-level decision points: what is known, what is uncertain, what should be handled by a licensed clinician, and what should be avoided because it creates dosing, safety, or access risk.
FAQ
Does Ambetter cover Zepbound? Varies dramatically by state and plan. Some states cover; others exclude.
What is Ambetter? Centene's ACA marketplace brand in approximately 30 states.
Why does Ambetter coverage vary by state? State-specific licensing, formulary decisions, and essential health benefit benchmarks.
What is the prior authorization process at Ambetter? State-specific PA with BMI, comorbidities, or OSA documentation.
How much does Zepbound cost with Ambetter? Covered: $50 to $400 depending on metal tier. Uncovered: $1,000 retail or LillyDirect $349 to $499.
Does the ACA require Ambetter to cover Zepbound? No; coverage is determined by state benchmark plans, not federal mandate.
Can I appeal an Ambetter denial? Yes, internal and external state IRO review.
Does Ambetter cover Zepbound for OSA? Coverage has expanded since December 2024 in many state plans.
Sources
- FDA, Zepbound (tirzepatide) prescribing information, OSA label expansion, December 2024
- Malhotra A et al. Tirzepatide for Obstructive Sleep Apnea (SURMOUNT-OSA). New England Journal of Medicine. June 2024
- Jastreboff AM et al. SURMOUNT-1 trial. New England Journal of Medicine. 2022
- Affordable Care Act essential health benefits regulations, 45 CFR Part 156
- State essential health benefit benchmark plans, current editions
- Centene Corporation Ambetter formulary documents, 2026 plan year, state-specific
- Centers for Medicare and Medicaid Services, Marketplace plan oversight materials
- Centene Corporation 2024 annual report
- Eli Lilly, LillyDirect Zepbound self-pay vial program, 2025-2026
- Kaiser Family Foundation, ACA marketplace enrollment and benefit data, 2024-2025
Footer disclaimers
Platform Disclaimer. FormBlends is a telehealth platform connecting patients with licensed clinicians and 503A compounding pharmacy partners. FormBlends has no relationship with Ambetter, Centene Corporation, or Eli Lilly. Coverage data reflects publicly available information as of May 2026 and varies meaningfully by state.
Compounded Medication Notice. Compounded tirzepatide is a 503A pharmacy product, not FDA-approved, and not interchangeable with brand-name Zepbound. Compounded preparations have different regulatory status than FDA-approved products.
Results Disclaimer. Weight loss, AHI improvement, and metabolic outcomes from clinical trial data reflect average effects in study populations. Individual response varies by dose tolerability, adherence, and baseline status.
Trademark Notice. Zepbound is a registered trademark of Eli Lilly and Company. Ambetter is a registered service mark of Centene Corporation. References are informational.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →